Sevelamer Carbonate Tablet, Film Coated
Product Images NDC 16714-814

5 FDA label images from Northstar Rx Llc · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Sevelamer Carbonate (NDC 16714-814). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Northstar Rx Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Figure 2. Change In Serum Phosphorus (mg/dl) From Baseline To Week 2 By Subgroup (Sevelamer Fig1)

Figure 2. Change In Serum Phosphorus (mg/dl) From Baseline To Week 2 By Subgroup (Sevelamer Fig1)
A horizontal forest plot titled 'Change in Serum Phosphorus (mg/dL) from Baseline to Week 2 by Subgroup,' showing least squares mean differences and 95% confidence intervals for subgroups including screening BSA, baseline serum phosphorus, age, and dialysis status. The x-axis ranges from -5 to 5, with a reference line at 0, indicating effects favoring Sevelamer Carbonate versus placebo.*
FDA Label Image

Figure 3. Percentage Of Patients (y-axis) Attaining A Phosphorus Reduction From Baseline (mg/dl) At Least As Great As The Value Of The X-axis. (Sevelamer Fig2)

Figure 3. Percentage Of Patients (y-axis) Attaining A Phosphorus Reduction From Baseline (mg/dl) At Least As Great As The Value Of The X-axis. (Sevelamer Fig2)
A line graph showing the percentage of patients achieving phosphorus reduction from baseline (Y-axis) at various levels of serum phosphorus reduction (mg/dL) on the X-axis. It compares two treatments: Sevelamer Hydrochloride and an active control, illustrating patient response to phosphorus reduction over the measured range.*
FDA Label Image

Figure 4. Mean Phosphorus Change From Baseline For Patients Who Completed 52 Weeks Of Treatment (Sevelamer Fig3)

Figure 4. Mean Phosphorus Change From Baseline For Patients Who Completed 52 Weeks Of Treatment (Sevelamer Fig3)
Line graph titled 'Mean Phosphorus Change from Baseline for Patients who Completed 52 Weeks of Treatment' showing phosphorus change on the y-axis and study week on the x-axis. The graph compares two treatments: Sevelamer Hydrochloride and an active control over 52 weeks, with phosphorus change decreasing initially and stabilizing over time.*
FDA Label Image

Package Label-principal Display Panel (800 mg (270 Tablets Bottle))

Package Label-principal Display Panel (800 mg (270 Tablets Bottle))
Label for Sevelamer Carbonate Tablets 800 mg film-coated oral tablets. The package contains 270 tablets. Manufactured for NorthStar Rx LLC, Memphis, TN, and by Aurobindo Pharma Limited, India. Label includes storage instructions, active and inactive ingredients, and a barcode.*
FDA Label Image

Chemical Structure (Sevelamer Str)

Chemical Structure (Sevelamer Str)
Chemical structure of Sevelamer Carbonate showing polymeric chains with primary amine groups, crosslinking groups, and bicarbonate ions, representing its extended polymer network.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.